Literature DB >> 3370193

Mephenytoin hydroxylation in the Cuna Amerindians of Panama.

T Inaba1, L F Jorge, T D Arias.   

Abstract

1 Mephenytoin p(4')-hydroxylation, which is deficient in 3-5% of Caucasians, was examined in 96 Cuna Amerindians of Panama. 2 Attempts were made to exclude poor compliance with urine collection and ingestion of the drug dose since the assignment of phenotype was based upon urinary recovery of the metabolite. These involved the measurement of the urinary recovery of sparteine, added to the ingested capsule, and of the renal excretion of creatinine. 3 Of the 90 Cunas deemed to be reasonably complaint, none of them appeared to be deficient in p(4')-hydroxylation of mephenytoin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3370193      PMCID: PMC1386617          DOI: 10.1111/j.1365-2125.1988.tb03284.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  [Preliminary study of the phenotype for acetylation in Teribe Amerindians].

Authors:  T D Arias; L F Jorge; G Núñez; T Inaba
Journal:  Rev Med Panama       Date:  1987-01

2.  Family studies of mephenytoin hydroxylation deficiency.

Authors:  T Inaba; M Jurima; W Kalow
Journal:  Am J Hum Genet       Date:  1986-05       Impact factor: 11.025

3.  No evidence for the presence of poor metabolizers of sparteine in an Amerindian group: the Cunas of Panama.

Authors:  T D Arias; L F Jorge; T Inaba
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

4.  Migration and genetic infrastructure of the Central American Guaymi and their affinities with other tribal groups.

Authors:  R Barrantes; P E Smouse; J V Neel; H W Mohrenweiser; H Gershowitz
Journal:  Am J Phys Anthropol       Date:  1982-06       Impact factor: 2.868

5.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

Authors:  K Nakamura; F Goto; W A Ray; C B McAllister; E Jacqz; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

6.  The genetic defect of mephenytoin hydroxylation.

Authors:  W Kalow
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

7.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.

Authors:  M Jurima; T Inaba; D Kadar; W Kalow
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

9.  Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.

Authors:  P J Wedlund; W S Aslanian; C B McAllister; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

  9 in total
  9 in total

1.  Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population.

Authors:  B S Doshi; R D Kulkarni; B L Chauhan; G R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

Review 2.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

3.  Microevolution in lower Central America: genetic characterization of the Chibcha-speaking groups of Costa Rica and Panama, and a consensus taxonomy based on genetic and linguistic affinity.

Authors:  R Barrantes; P E Smouse; H W Mohrenweiser; H Gershowitz; J Azofeifa; T D Arias; J V Neel
Journal:  Am J Hum Genet       Date:  1990-01       Impact factor: 11.025

4.  Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study.

Authors:  Jorge Vicente; Fabricio González-Andrade; Antonia Soriano; Ana Fanlo; Begoña Martínez-Jarreta; Blanca Sinués
Journal:  Mol Biol Rep       Date:  2014-01-16       Impact factor: 2.316

Review 5.  Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Authors:  Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó
Journal:  Pharmacogenomics       Date:  2016-09-16       Impact factor: 2.533

Review 6.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico.

Authors:  Joel Salazar-Flores; Luis A Torres-Reyes; Gabriela Martínez-Cortés; Rodrigo Rubi-Castellanos; Martha Sosa-Macías; José F Muñoz-Valle; César González-González; Angélica Ramírez; Raquel Román; José L Méndez; Andrés Barrera; Alfredo Torres; Rafael Medina; Héctor Rangel-Villalobos
Journal:  Genet Test Mol Biomarkers       Date:  2012-08-22

8.  Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.

Authors:  R J Guttendorf; M Britto; R A Blouin; T S Foster; W John; K A Pittman; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

9.  Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals.

Authors:  Carlos Isaza; Julieta Henao; José H Isaza Martínez; Juan C Sepúlveda Arias; Leonardo Beltrán
Journal:  BMC Clin Pharmacol       Date:  2007-07-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.